Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BillionToOne, Inc. Class A ( (BLLN) ) has shared an update.
On January 12, 2026, BillionToOne, Inc. announced financial guidance indicating it expects to maintain previously reiterated full-year 2025 revenue in the range of $293 million to $299 million with positive GAAP operating income, and projected that full-year 2026 revenue will rise to between $415 million and $430 million, implying 40% to 45% growth versus the midpoint of its 2025 outlook while remaining GAAP operating income positive. The company framed this guidance as evidence of its ability to scale its differentiated molecular diagnostics platform and deepen its role in addressing significant clinical needs, signaling continued operational momentum and a strengthening growth profile for investors and other stakeholders as it advances its technology and commercial footprint.
The most recent analyst rating on (BLLN) stock is a Hold with a $94.00 price target. To see the full list of analyst forecasts on BillionToOne, Inc. Class A stock, see the BLLN Stock Forecast page.
Spark’s Take on BLLN Stock
According to Spark, TipRanks’ AI Analyst, BLLN is a Neutral.
The score is held back mainly by continued losses and cash burn in the financial statements and weak near-term technicals (below the 20-day average with negative MACD). These are partially offset by a strong earnings-call picture—rapid growth, expanding gross margin, and an inflection to positive GAAP operating margin with upbeat revenue guidance—while valuation support is limited due to a negative P/E and no dividend yield provided.
To see Spark’s full report on BLLN stock, click here.
More about BillionToOne, Inc. Class A
BillionToOne, Inc. is a Menlo Park, California-based, next-generation molecular diagnostics company focused on developing powerful and accurate tests that are accessible to a broad patient population. Its offerings are built on a patented Quantitative Counting Templates (QCT) molecular counting platform, a multiplex technology designed to accurately count DNA molecules at the single-molecule level, positioning the company within the high-growth precision diagnostics and genomics testing markets.
Average Trading Volume: 238,245
Current Market Cap: $4.01B
See more data about BLLN stock on TipRanks’ Stock Analysis page.